ADPT

Adaptive Biotechnologies Corporation

A maker of tools that read the immune system's genetic code. Its FDA-authorized clonoSEQ test hunts for the tiny traces of cancer cells that can linger after treatment for blood cancers like multiple myeloma, helping doctors spot a possible relapse early. The company was founded in 2009 by brothers Harlan and Chad Robins, after Harlan's lab work at a Seattle research center cracked how to sequence T-cell receptors; Chad, a business guy who joked he couldn't tell a T-cell receptor from a T-bone steak, handled the company side.

Recent Activity

Show $

2026Q2

4 sells

ARK Genomic Revolution ETFTRIM

-25.7K shares(-1.2%)

ARK Genomic Revolution ETFTRIM

-25.7K shares(-1.2%)

ARK InvestTRIM

-2.7K shares(-0.1%)

ARK InvestTRIM

-2.7K shares(-0.1%)

Bridgewater Associates LPTRIM

-49.6K shares(-55.3%)

Bridgewater Associates LPTRIM

-49.6K shares(-55.3%)

Polen Capital ManagementTRIM

-13.6K shares(-11.7%)

Polen Capital ManagementTRIM

-13.6K shares(-11.7%)

2026Q1

4 sells

ARK Genomic Revolution ETFTRIM

-674.6K shares(-23.9%)

ARK Genomic Revolution ETFTRIM

-674.6K shares(-23.9%)

ARK InvestTRIM

-46.0K shares(-2.2%)

ARK InvestTRIM

-46.0K shares(-2.2%)

Bridgewater Associates LPTRIM

-175.8K shares(-66.2%)

Bridgewater Associates LPTRIM

-175.8K shares(-66.2%)

Polen Capital ManagementTRIM

-209.7K shares(-64.4%)

Polen Capital ManagementTRIM

-209.7K shares(-64.4%)

Loading more activity...